XOMA Royalty (NASDAQ:XOMA) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• XOMA Royalty has received a reiterated "sell (D-)" rating from Weiss Ratings, amid mixed assessments from other analysts, including upgrades and downgrades.
• Despite a recent stock price increase of 2.5% to $35.13, XOMA Royalty's market cap stands at approximately $424.59 million with reported earnings of $0.48 per share for the last quarter.
• Insider trading activity includes CFO Thomas M. Burns selling 4,330 shares, indicating a 12.58% reduction in his holdings, while institutional investors own about 95.92% of the stock.

XOMA Royalty (NASDAQ:XOMA - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities research analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

XOMA has been the subject of a number of other reports. Wall Street Zen raised shares of XOMA Royalty from a "hold" rating to a "buy" rating in a research note on Monday, August 11th. Zacks Research lowered shares of XOMA Royalty from a "strong-buy" rating to a "hold" rating in a research note on Monday. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $69.50.

XOMA Royalty Trading Up 2.5%

Shares of XOMA stock traded up $0.86 on Friday, hitting $35.13. The stock had a trading volume of 21,071 shares, compared to its average volume of 46,029. XOMA Royalty has a twelve month low of $18.35 and a twelve month high of $39.92. The firm has a market cap of $424.59 million, a P/E ratio of -22.66 and a beta of 1.02. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 1.41. The company has a fifty day moving average price of $35.74 and a two-hundred day moving average price of $28.73.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.60. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. The company had revenue of $13.13 million during the quarter, compared to analyst estimates of $9.39 million. As a group, analysts forecast that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Thomas M. Burns sold 4,330 shares of the company's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $35.99, for a total value of $155,836.70. Following the completion of the transaction, the chief financial officer directly owned 30,079 shares of the company's stock, valued at approximately $1,082,543.21. This represents a 12.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.10% of the company's stock.

Hedge Funds Weigh In On XOMA Royalty

A number of large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its stake in shares of XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,523 shares during the last quarter. Opaleye Management Inc. boosted its stake in shares of XOMA Royalty by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company's stock worth $6,428,000 after buying an additional 2,044 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of XOMA Royalty during the 2nd quarter worth about $116,000. Occudo Quantitative Strategies LP acquired a new position in shares of XOMA Royalty during the 2nd quarter worth about $527,000. Finally, Marshall Wace LLP boosted its stake in shares of XOMA Royalty by 12.2% during the 2nd quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company's stock worth $411,000 after buying an additional 1,775 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.